Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for blood cancer patients: STP938 trial targets tough cases

NCT ID NCT06786234

Disease control Sponsor: Step Pharma, SAS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests STP938, a daily pill, in 50 adults with high-risk essential thrombocythaemia who cannot use standard therapy. The goal is to see if it safely lowers high platelet counts and reduces complications like blood clots. Participants take the drug for up to 12 months with regular clinic visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
STP938
What this could lead to
If it works, this could offer a new treatment option for people with essential thrombocythaemia who cannot take or do not respond to current therapy.
What could go wrong
This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The drug may cause side effects or fail to control platelet counts long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Adults aged 18 years or older * A confirmed diagnosis of ET according to World Health Organisation (WHO) or British Society for Haematology (BSH) criteria. * Meeting criteria for high risk ET. * Raised platelet count (\>600 x109/L) requiring cytoreductive therapy. * Neutrophil count \>1.0 x109/L. * Either intolerant of or resistant to hydroxycarbamide having met any one of the criteria at any point in their disease whilst receiving hydroxycarbamide. * Adequate hepatic function. * Adequate blood coagulation parameters. * Eastern Cooperative Oncology Group (ECOG) status of 0-2. Key Exclusion Criteria: * Subjects currently or recently receiving cytoreductive therapy for the treatment of essential thrombocythaemia (wash out periods apply). * Subjects who have received any investigational agents for the treatment of essential thrombocythaemia within 4 weeks before enrolment or less than 5 half-lives since completion of prior therapy, whichever is shorter. * Proven or suspected transformation to polycythaemia vera, myelofibrosis, myelodysplasia, acute myeloid leukaemia or another myeloid neoplasm. * Known malabsorption syndrome or other condition that may impair absorption of study medication (e.g. gastrectomy). * Previous splenectomy. * Any uncontrolled intercurrent illness. * Immunocompromised subjects with increased risk of opportunistic infections. * Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection. * Pregnant females, breastfeeding females, and women of child bearing age or males not willing to comply with contraceptive requirements. * Known hypersensitivity to any of the excipients used in the formulation of the study drug. * Corrected QT interval \>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential thrombocythemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential thrombocythaemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Brest

    RECRUITING

    Brest, France

  • CHU Nantes

    RECRUITING

    Nantes, France

  • CHU Nice

    RECRUITING

    Nice, France

  • CHU Nîmes

    RECRUITING

    Nîmes, France

  • Cancer and Haematology Centre, Churchill Hospital

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Gustave Roussy

    RECRUITING

    Villejuif, France

  • Hôpital Saint-Louis

    RECRUITING

    Paris, France

  • Hôpital de la Milétrie, CHU

    NOT_YET_RECRUITING

    Poitiers, New Aquitaine, 86021, France

  • Imperial College London / Hammersmith Hospital

    RECRUITING

    London, United Kingdom

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, France

  • Royal Hallamshire Hospital

    RECRUITING

    Sheffield, South Yorkshire, S10 2JF, United Kingdom

  • Sarah Cannon Research Institute

    RECRUITING

    London, United Kingdom

  • University Hospital of Wales

    RECRUITING

    Cardiff, United Kingdom

  • University of Southampton Hospital

    RECRUITING

    Southampton, United Kingdom